Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 4,019 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part 3 Clear all
Completed Phase 3 Interventional Results available

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

NCT02371369
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
Interventions
Pexidartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Nov 9, 2026, 10:12 PM EST
Terminated Phase 1 Interventional

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

NCT05769959
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions
RO7515629, tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Nov 9, 2026, 10:12 PM EST
Completed No phase listed Observational

Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects

NCT02302196
View directory record Official record
Conditions
Cancer of the Breast, Anomaly of Breast
Interventions
Autologous Fat Grafting of the Breast, Control Arm
Procedure · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Clackamas, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Nov 9, 2026, 10:12 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

NCT01677741
View directory record Official record
Conditions
Neoplasms, Brain
Interventions
Dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
8
States / cities
Phoenix, Arizona • Orange, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 9, 2026, 10:12 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

NCT02637687
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 21 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Nov 9, 2026, 10:12 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Health and Wellness in Healthcare Providers Post-disaster

NCT03722368
View directory record Official record
Conditions
Intervention 1: Resilience and Coping for Healthcare Group, Intervention 2: Resilience and Coping for Healthcare Plus Additional Services, Waitlist Control Group
Interventions
RCHC+, Waitlist control
Behavioral · Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Nov 9, 2026, 10:12 PM EST
Terminated Phase 4 Interventional Results available

Enterra Therapy Gastric Stimulation System

NCT00556166
View directory record Official record
Conditions
Gastroparesis
Interventions
Enterra Therapy Gastric Stimulator
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Nov 9, 2026, 10:12 PM EST
Terminated Phase 1 Interventional

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

NCT03355066
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
SM08502
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Nov 9, 2026, 10:12 PM EST
Terminated No phase listed Observational

Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis

NCT03929822
View directory record Official record
Conditions
Breast Screening
Interventions
Contrast-Enhanced Spectral Mammography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Nov 9, 2026, 10:12 PM EST
Recruiting Phase 1 Interventional

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

NCT06233110
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Fostamatinib, Ruxolitinib
Drug
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 9, 2026, 10:12 PM EST
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

NCT01889862
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
BMN165 20mg/day, BMN165 40mg/day, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
29
States / cities
La Jolla, California • Oakland, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Nov 9, 2026, 10:12 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

NCT01835561
View directory record Official record
Conditions
Clinical Pharmacology, Healthy Volunteer Study
Interventions
Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Nov 9, 2026, 10:12 PM EST
Recruiting Not applicable Interventional

Development of a Personalized, Psychosocial Intervention for Menopausal Individuals With Elevated Dementia Risk

NCT06965686
View directory record Official record
Conditions
Menopausal, Dementia
Interventions
PERI-MIND
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 58 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Nov 9, 2026, 10:12 PM EST
Recruiting Phase 2 Interventional

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Venetoclax
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 9, 2026, 10:12 PM EST
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

NCT01803282
View directory record Official record
Conditions
Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer
Interventions
Andecaliximab, Gemcitabine, Nab-paclitaxel, Carboplatin, Pemetrexed, Leucovorin, Oxaliplatin, 5-FU, Bevacizumab, Irinotecan, Paclitaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Nov 9, 2026, 10:12 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

NCT06995820
View directory record Official record
Conditions
Healthy
Interventions
AZD1613, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 9, 2026, 10:12 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

NCT06508320
View directory record Official record
Conditions
Influenza, SARS-CoV-2
Interventions
mRNA-1083
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
931 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
12
States / cities
Hialeah, Florida • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 9, 2026, 10:12 PM EST
Not listed Phase 1 Interventional

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

NCT04460456
View directory record Official record
Conditions
HER2 Positive Solid Tumors
Interventions
SBT6050, pembrolizumab, Cemiplimab
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Nov 9, 2026, 10:12 PM EST
Not listed Not applicable Interventional

Dialogue Around Respiratory Illness Treatment

NCT02943551
View directory record Official record
Conditions
Respiratory Disease, Acute Respiratory Infection, Respiratory Infection, Upper Respiratory Infection
Interventions
Online Tutorial, Webinars, Booster Sessions, Feedback Reports, Parent Survey
Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Months to 10 Years
Enrollment
2,728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
20
States / cities
Paragould, Arkansas • Eureka, California • Durango, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Nov 9, 2026, 10:12 PM EST
Not listed Not applicable Interventional

Behavioral Economics Intervention to Increase Treatment Seeking in the National Guard

NCT04098588
View directory record Official record
Conditions
Treatment Refusal
Interventions
BEAST, Descriptive Feedback
Behavioral
Lead sponsor
University of Southern Mississippi
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Nov 9, 2026, 10:12 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion

NCT07639827
View directory record Official record
Conditions
Wellness, Self Compassion, Burnout, Anxiety, Depression
Interventions
App-based bundled mental fitness intervention, App-based wellness module collection
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 9, 2026, 10:12 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

NCT05164094
View directory record Official record
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1189, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
10 Years to 30 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
65
States / cities
Huntsville, Alabama • Anaheim, California • Colton, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 9, 2026, 10:12 PM EST
Terminated Phase 2 Interventional

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

NCT04318145
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 9, 2026, 10:12 PM EST
Withdrawn Not applicable Interventional

Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment (Part 2)

NCT00558194
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training, Standard Behavioral Weight Loss Treatment
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Nov 9, 2026, 10:12 PM EST